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Gutkind, 2007), and perhaps
of antitumorigenic endocan-
nabinoids (Guzma´n, 2003;
Wang et al., 2008). Second,
their study also unveiled that
the low FFA levels and
impaired growth of MAGL
knocked-down cancer cells
in xenografted mice can be
rescued by feeding the
animals a high-fat diet. What
is the precise role of the
MAGL-FFA connection in the
crosstalk between obesity
and tumorigenesis? Its
possible link with dietary
restriction and the oncogenic
phosphatidylinositol 3-kinase
pathway (Kalaany and Saba-
tini, 2009) could specifically
be examined. Third, it was
also shown that MAGL-
silenced cancer cells display
enhanced sensitivity to the antimigratory
and antisurvival effects of an epidermal
growth factor receptor tyrphostin. Could
MAGL inhibitors render human tumors
more responsive to the antineoplastic
action of tyrosine kinase-targeted chemo-
therapeutic drugs? Although acute/
pharmacological and sustained/genetic
loss of MAGL function generated some-
what distinct metabolomic profiles in the
cancer cells studied, the work by Nomura
et al. (2010) turns MAGL into an unex-
pected and exciting new candidate for
cancer therapy.
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Brownell et al. (2010) elucidate the mechanism of action of MLN4924, a NEDD8-activating enzyme inhibitor.
MLN4924 requires the activity of the enzyme to generate a NEDD8-adenylate analog that potently and selec-
tively shuts down this posttranslational modification system.
The covalent modification of proteins with
ubiquitin (Ub) and ubiquitin-like proteins
(UbLs) is widely appreciated as a major
eukaryotic posttranslational regulatory
mechanism. To date, nine classes of
UbLs with varying degrees of identity to
Ub have been identified in humans (Schul-
man and Harper, 2009). In addition to
Ub’s well appreciated role in promoting
protein destruction by the 26S protea-
some, Ub and UbLs have numerous other
functions to rapidly and conditionally alter
protein function, such as changing protein
localization, regulating other posttransla-
tional modifications, and modulating
protein-protein interactions.
Ub and UbLs share similar enzymatic
mechanisms for their conjugation onto
target proteins. Their entry into a conjuga-
tion pathway first requires ATP-dependent
activation through the formation of an ad-
enylate intermediate in the nucleotide
binding pocket of their cognate E1 (acti-
vating enzyme) (Ciechanover et al., 1981;
Haas et al., 1982). After this occurs, the
activated molecule is transferred onto the
catalytic cysteine of E1, an acceptor
Figure 2. The Three Ages of MAGL
(A) MAGL catalyzes the final step of lipolysis in adipocytes, thus providing
tissues with FFA fuel.
(B) MAGL deactivates 2-AG in neurons, thus tuning endocannabinoid
signaling.
(C) MAGL controls FFA generation in cancer cells, thus allowing them to
produce oncogenic lipid signals.
AA, arachidonic acid; AT, acyltransferase; COX, cylooxygenase; DAGL, sn-1
DAG lipase; Pase, lipid phosphatase. Other abbreviations are in the text.
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sulhyrdryl, to form a high energy thiolester
intermediate. The transfer of the thiolesteri-
fied molecule from an E1 to an E2 (conju-
gating enzyme) catalytic cysteine requires
a ‘‘fully loaded’’ E1 complex with two
bound molecules—one in its adenylate
form and the other linked via a thiolester
bond—with associated dramatic changes
in enzyme conformation (Huang et al.,
2007). The molecule is ultimately and
covalently transferred when the primary
amine of a lysine side chain of a protein
substrate is positionedsuch that it destabi-
lizes the thiolester linkage, promoting
peptide bond formation. This usually
involves E3s (ligases) that interact with
protein substrates and activated E2s to
facilitate this reaction.
Recent work by Soucy et al. (2009a) re-
ported the characterization of MLN4924,
the first cell-permeable inhibitor that
selectively targets the E1 for the UbL
NEDD8. The major targets for NEDD8
modification (neddylation) are cullin pro-
teins that function as part of the catalytic
core of cullin-RING ubiquitin ligases
(CRLs) (Petroski and Deshaies, 2005).
Reversible neddylation of cullins regu-
lates CRL assembly and the presence of
NEDD8 on CRLs enhances substrate
ubiquitination by increasing the recruit-
ment of Ub-charged E2s and promoting
covalent Ub transfer. By inhibiting this
E1’s activity, MLN4924 effectively evis-
cerates downstream activities such as
activation of the NEDD8 E2 UBC12 and
cullin neddylation, ultimately leading to
the accumulation of CRL substrates nor-
mally targeted for degradation by the
26S proteasome. As many of these
substrates have critical roles regulating
cell cycle progression, DNA replication,
and DNA damage response mechanisms,
cells treated with MLN4924 manifest hall-
marks related to alterations in these and
undergo apoptosis.
Remarkably, MLN4924 slows tumor
growth in mouse xenograft studies and
appears well tolerated at a variety of
doses and treatment regimens (Soucy
et al., 2009a). Given the involvement of
CRLs and consequently neddylation in
a myriad of processes required in all cells,
it is unclear why cancer cells are
more sensitive to NEDD8 E1 inhibition.
Nevertheless, MLN4924 appears to
have significant potential as an anti-
cancer therapeutic and several Phase 1
clinical trials are now underway by
Millennium Pharmaceuticals (Soucy et al.,
2009b).
In the present work, Brownell et al.
(2010) uncover a clever mechanism that
underlies how MLN4924 inhibits the
NEDD8 E1. MLN4924 forms a covalent
adduct with the carboxy terminus of
NEDD8 through its sulfamate group in
a process that requires NEDD8 on the
E1 active site and MLN4924 binding to
the E1 nucleotide binding pocket. A
hydrogen bond between oxygen atoms
in MLN4924 and the backbone amide of
Gly79 on the E1 b subunit lowers the
pKa of the sulfamate amino group,
thereby promoting its nucleophilicity.
This effectively destabilizes the thiolester
bond between NEDD8 and the E1 active
site cysteine and leads to covalent adduct
formation. Whereas the overall structure
of the E1 in the presence of NEDD8,
ATP, and MLN4924 appeared similar to
those previously reported for it with
NEDD8 and ATP (Walden et al., 2003;
Huang et al., 2007), a 45 rotation of the
NEDD8 G76 backbone with a 1 A˚ shift of
the sulfamate sulfur atom on MLN4924
brings the reactants in close enough prox-
imity to promote covalent bond forma-
tion. Experiments employing a NEDD8-
MLN4924-specific antibody detected
adduct accumulation with concomitant
loss of neddylated cullins and accumula-
tion of free NEDD8 after treating cells for
only 5 min with the compound.
The inhibitory product generated by
MLN4924 with NEDD8 resembles an
Ub-adenylate analog (adenosyl-phospho-
ubiquitinol, APU), previously shown to
inhibit the Ub E1 UBE1 (Wilkinson et al.,
1990). APU binds directly to the nucleo-
tide binding pocket to function as
a competitive inhibitor with respect to
ATP and a noncompetitive inhibitor with
respect to Ub. ATP-PPi exchange experi-
ments that employ E1 lacking a catalytic
cysteine to isolate the initial step in
NEDD8 activation determined that
MLN4924 alone does not inhibit ATP
binding. Thus, the initial reactions
required for NEDD8 activation by E1—
formation of a NEDD8-adenylate interme-
diate and transfer to the E1 active site—
are a prerequisite for MLN4924 to bind
and react with NEDD8 to form the
NEDD8-MLN4924 adduct. The small
size of MLN4924 presumably allows it to
enter cells to rapidly react with the
NEDD8 charged E1, conferring its ability
to inhibit a variety of NEDD8 associated
functions from E1 activation to cullin
neddylation.
The similar activation mechanisms and
conservation of Gly79 (described above)
in all known Ub and UbL E1s suggest
compounds analogous to MLN4924
should selectively modulate activities of
E1s through similar mechanism-based
inhibition. Such molecules would provide
not only invaluable basic research tools,
but may also have utility as therapeutic
agents. The authors provide proof of
principle through ‘‘Compound One,’’ an
analog of MLN4924 that functions as
a pan inhibitor for the two Ub E1s as well
as for those for NEDD8, SUMO, ISG15,
and GABARAP in vitro. Thus, further
efforts to fine tune various MLN4924
analogs may ultimately yield a variety of
E1-selective inhibitors.
It is widely appreciated that the Ub and
UbL protein modification systems have
a variety of potential targets for thera-
peutic development efforts (Nalepa
et al., 2006). To date, however, the pro-
teasome inhibitor bortezomib (Velcade,
also by Millennium Pharmaceuticals) rep-
resents the only commercially available
drug directly targeting any aspect of these
systems. Given the involvement of the
26S proteasome in protein homeostasis
mechanisms, it is not surprising that bor-
tezomib has toxicity issues and a variety
of side effects. The ability of MLN4924
to selectively inhibit neddylation path-
ways, but not impact bulk protein turn-
over, and potently slow tumor growth in
mouse xenograft studies (Soucy et al.,
2009a) highlight the exciting potential of
this molecule. The work by Brownell
et al. (2010) provides important insight
into MLN4924’s mechanism of action
and increases the anticipation of the forth-
coming results from its clinical trials.
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A recent study by Thomas O’Halloran and his group at Northwestern University (Avarez et al. Sciencexpress,
www.scienceexpress.org, 26 November 2009) has provided insights into how tetrathiomolybdate inhibits
copper-trafficking proteins through metal cluster formation. The broader context of the work provides an
attractive explanation of the long recognized but poorly understood antagonistic effects of Mo and Cu in
living organisms.
The relationship between copper and
molybdenum as trace nutrients goes
back many decades and was of particular
importance to sheep farmers
in Scotland, where the high
molybdenum content of the
soils and peats in the Scottish
highlands led to severe
copper deficiency in sheep.
Solutions to such questions
usually emerge incrementally
but in their recent Science
paper, the O’Halloran labora-
tory presents the results of
a structural study of the inter-
action of tetrathiomolybdate
with a copper chaperone
Atx1 that provides a compre-
hensive explanation for many
of the observed interactions
between copper and molyb-
denum in living cells.
When tetrathiomolybdate
(TM) was reacted with
copper-loaded Atx1, a purple
complex was formed that
gave rise to crystals diffract-
ing to 2.3 A˚. Solution of the
structure revealed an unusual
multinuclear cluster formed
by the interaction of the thio
groups of TM with each of three Atx1
Cu(I) centers (Figure 1). TM did not re-
move copper from the chaperone as the
researchers had anticipated, but rather it
recruited copper-loaded chaperone
molecules into an oligomeric complex.
Since the overall stoichiom-
etry was S6Cu4MoS4, the
cluster must recruit one addi-
tional copper atom, perhaps
from a fourth Atx1 molecule
that is converted to its apo
form. They showed further
that TM efficiently inhibited
the transfer of copper from
Atx1 to its physiological
partner, the Ccc2 ATPase.
TM is a promising candidate
for the treatment of Wilson
disease, in which copper
accumulates in liver, kidney
,and brain as the result of
a defect in the efflux pump
ATP7B. The authors were
quick to recognize that the
EXAFS spectra at both the
Cu and Mo K edges closely
resemble those published in
2009 by Zhang et al. on
complexes formed in the
livers of LP rats (an animal
model of Wilson disease)
who had been treated with
TM. The new crystal structure
Figure 1. Structure of the Novel S6Cu4MoS4Cluster Formed between
Tetrathiomolybdate and Three Molecules of the Copper Chaperone
Atx1
Reproduced with permission.
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